Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers

PURPOSE: Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such treatment. PATIENTS AND METHODS: In the NeoAva phase II clinical trial, patients (N = 132) with large (≥ 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Haugen, Mads H., Lingjærde, Ole Christian, Hedenfalk, Ingrid, Garred, Øystein, Borgen, Elin, Loman, Niklas, Hatschek, Thomas, Børresen-Dale, Anne-Lise, Naume, Bjørn, Mills, Gordon B., Mælandsmo, Gunhild M., Engebraaten, Olav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140811/
https://www.ncbi.nlm.nih.gov/pubmed/34036235
http://dx.doi.org/10.1200/PO.20.00086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140811/
https://www.ncbi.nlm.nih.gov/pubmed/34036235
http://dx.doi.org/10.1200/PO.20.00086

Ejemplares similares